The Journal of Urology
Volume 179, Issue 6 , Pages 2096-2102 , June 2008

Diagnostic and Prognostic Molecular Markers in Renal Cell Carcinoma

  • Hari S.G.R. Tunuguntla

      Affiliations

    • Corresponding Author InformationCorrespondence: Department of Urology, University of Miami/Jackson Memorial Hospital, 1400 Northwest 10th Ave., Miami, Florida 33136 (telephone: 305-243-3670; FAX: 305-243-5134).
    • ,
  • Merce Jorda

Received 10 September 2007

References 

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106
  2. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335:865
  3. Mufti GJ, Hamblin TJ, Stevens J. Basic isoferritin and hypercalcaemia in renal cell carcinoma. J Clin Pathol. 1982;35:1008
  4. Kikuchi H. Tumor markers of urinary tract carcinoma. Rinsho Byori. 2004;52:371
  5. Iwagaki H, Hizuta A, Tanaka N, Orita K. Plasma neopterin/C-reactive protein ratio as an adjunct to the assessment of infection and cancer cachexia. Immunol Invest. 1995;24:479
  6. Fumagalli L, Lissoni P, Di Felice G, Meregalli S, Valsuani G, Mengo S, et al. Pretreatment serum markers and lymphocyte response to interleukin-2 therapy. Br J Cancer. 1999;80:407
  7. Hofmockel G, Tsatalpas P, Muller H, Dammrich J, Poot M, Maurer-Schultze B, et al. Significance of conventional and new prognostic factors for locally confined renal cell carcinoma. Cancer. 1995;76:296
  8. Uchida T, Gao J, Wang C, Jiang S, Muramoto M, Satoh T, et al. Clinical significance of p53, mdm2, and bcl-2 proteins in renal cell carcinoma. Urology. 2002;59:615
  9. Zigeuner R, Ratschek M, Rehak P, Schips L, Langner C. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue. Urology. 2004;63:651
  10. Richter EN, Oevermann K, Buentig N, Storkel S, Dallmann I, Atzpodien J. Primary apoptosis as a prognostic index for the classification of metastatic renal cell carcinoma. J Urol. 2002;168:460
  11. Kralj M, Pavelic J. p21WAF1/CIP1 is more effective than p53 in growth suppression of mouse renal carcinoma cell line Renca in vitro and in vivo. J Cancer Res Clin Oncol. 2003;129:463
  12. Kashyap MK, Kumar A, Emelianenko N, Kashyap A, Kaushik R, Huang R, et al. Biochemical and molecular markers in renal cell carcinoma: an update and future prospects. Biomarkers. 2005;10:258
  13. Meria P, Toubert ME, Cussenot O, Bassi S, Janssen T, Desgrandchamps F, et al. Tumor-associated trypsin inhibitor and renal cell carcinoma. Eur Urol. 1995;27:223
  14. Chang CH, Wu HC, Yen RF, Kao A, Lin CC, Lee CC. Tissue polypeptide specific antigen (TPS) as a tumor marker in renal cell carcinoma. Anticancer Res. 2002;22:2949
  15. Zhang X, Takenaka I. Cell proliferation and apoptosis with BCL-2 expression in renal cell carcinoma. Urology. 2000;56:510
  16. Huang A, Fone PD, Gandour-Edwards R, White RW, Low RK. Immunohistochemical analysis of BCL-2 protein expression in renal cell carcinoma. J Urol. 1999;162:610
  17. Takashi M, Haimoto H, Tanaka J, Murase T, Kato K. Evaluation of gamma-enolase as a tumor marker for renal cell carcinoma. J Urol. 1989;141:830
  18. Hegle A, Varga Z, Kosche B, Stief T, Heidenreich A, Hofmann R. Pyruvate kinase type tumor M2 in urological malignancies. Urol Int. 2003;70:55
  19. Hara N, Bilim V, Kasahara T, Obara K, Saito K, Takahashi K, et al. Inducible nitric oxide, synthase in renal cell carcinoma: expression in tumor thrombi and induction under hypoxic conditions. Anticancer Res. 2003;23:4641
  20. Tatsumi T, Herrem CJ, Olson WC, Finke JH, Bukowski RM, Kinch MS, et al. Disease stage variation in CD4+/ and CD8+/T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res. 2003;63:4481
  21. Mizutani Y, Wada H, Yoshida O, Fukushima M, Nonomura M, Nakao M, et al. Significance of thymidylate synthase activity in renal cell carcinoma. Clin Cancer Res. 2003;9:1453
  22. Jung SM, Kuo TT. Immunoreactivity of CD10 and inhibin alpha in differentiating hemangioblastomas of central nervous system from metastatic clear cell renal cell carcinoma. Mod Pathol. 2005;18:788
  23. Bussolati B, Russo S, Deambrosis I, Cantaluppi V, Volpe A, Ferrando U, et al. Expression of CD154 on renal cell carcinomas and effect on cell proliferation, motility and platelet-activating factor synthesis. Int J Cancer. 2002;100:654
  24. Westenfelder C, Baranowski RL. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int. 2000;58:647
  25. Mejean A, Oudard S, Thiounn N. Prognostic factors of renal cell carcinoma. J Urol. 2003;169:821
  26. Pich A, Valente G, Azzoni L, Stramignoni A, Margaria E, Tasso M. Argyrophilic nucleolar organizer region counts and Ki-67 scores in human renal cell carcinoma. Pathol Res Pract. 1991;187:482
  27. Pich A, Chiusa L, Margaria E. Role of the argyrophilic nucleolar organizer regions in tumor detection and prognosis. Cancer Detect Prev. 1995;19:282
  28. Delahunt B, Eble JN, McCredie MR, Bethwaite PB, Stewart JH, Bilous AM. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum Pathol. 2001;32:590
  29. Yoshida SO, Imam A. Monoclonal antibody to a proximal nephrogenic renal antigen: immunohistochemical analysis of formalin-fixed, paraffin-embedded human renal cell carcinomas. Cancer Res. 1989;49:1802
  30. Mantur M, Kemona H, Pietruczuk M, Wasiluk A. Does renal carcinoma affect the expression of P-selectin on platelets?. Neoplasma. 2002;49:243
  31. Murakami Y, Kanda K, Tsuji M, Kanayama H, Kagawa S. MN/CA9 gene expression as a potential biomarker in renal cell carcinoma. BJU Int. 1999;83:743
  32. Liao SY, Aurelio ON, Jan K, Zavada J, Stanbridge EJ. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res. 1997;57:2827
  33. Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003;9:802
  34. Rini BI. Current status and future directions of molecular markers in renal cell carcinoma. Curr Opin Urol. 2006;16:332
  35. Lee CT, Genega EM, Hutchinson B, Fearn PA, Kattan MW, Russo P, et al. Conventional (clear cell) renal carcinoma metastases have greater bcl-2 expression than high-risk primary tumors. Urol Oncol. 2003;21:179
  36. Figlin RA, Seligson D, Wu H, Thomas G, Leppert JT, O'Toole T, et al. Characterization of the mTOR pathway in renal cell carcinoma and its use in predicting patient selection for agents targeting this pathway. J Clin Oncol. 2005;23:387s;abstract 4539
  37. Horiguchi A, Oya M, Shimada T, Uchida A, Marumo K, Murai M. Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome. J Urol. 2002;168:762
  38. Rabbani F, Herr HW, Almahmeed T, Russo P. Temporal change in risk of metachronous contralateral renal cell carcinoma: influence of tumor characteristics and demographic factors. J Clin Oncol. 2002;20:2370
  39. Bast RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883

 For another article on a related topic see page 2416.

PII: S0022-5347(08)00230-9

doi: 10.1016/j.juro.2008.01.083

The Journal of Urology
Volume 179, Issue 6 , Pages 2096-2102 , June 2008

Article Tools

* Image Usage & Resolution